FENC 4.64 (+8.41%)
CA31447P1009BiotechnologyBiotechnology

Fennec Pharmaceuticals (FENC) Stock Highlights

4.64 | +8.41%
2024-11-21 05:46:49
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

Statistics

Range Today
4.21 4.79
Volume Today 190.8K
Range 1 Year
3.96 11.92
Volume 1 Year 30.41M
Range 3 Year
3.82 11.92
Volume 3 Year 78.71M
Range 10 Year
3.26 14.99
Volume 10 Year 189.66M

Highlights

Market Capitalization 118M (small)
Floating Shares 14.84M
Current Price 4.64
Price To Earnings 61.57
Price To Revenue 2.17
Earnings Per Share 0.07
Payout Ratio 0%

Performance

Latest +8.41%
1 Month +0.43%
3 Months -17.88%
6 Months -34.56%
1 Year -43.76%
3 Years -53.27%
5 Years -11.95%
10 Years -63.03%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.